Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 5:21 PM
Ignite Modification Date:
2025-12-24 @ 5:21 PM
NCT ID:
NCT03084250
Brief Summary:
The CHB subjects who are cirrhosis, will be randomized to two groups.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
Detailed Description:
This study is a prospective, randomized, open-label study.
The CHB subjects who are cirrhosis will be randomized to two groups.
The subjects who go into group A will be treated by nucleotide analogue (NA) combination with peginterferon alfa-2a,180μg/week for 48 weeks.
The subjects who go into group B will be treated by nucleotide analogue (NA) only for 48 weeks.
Study:
NCT03084250
Study Brief:
Protocol Section:
NCT03084250